SCHEMBL715925

SCHEMBL715925

CN(C)c1ncnc(Cl)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.39
CYP1A2 P05177 2/20 0.39
LMNA P02545 1/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
CREBBP Q92793 1/20 0.39
DYRK1A Q13627 6/20 0.38
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 2/20 0.33
DYRK3 O43781 1/20 0.33
CLK1 P49759 1/20 0.33
CLK2 P49760 1/20 0.33
CLK3 P49761 1/20 0.33
JAK3 P52333 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
PNCK Q6P2M8 1/20 0.33
HASPIN Q8TF76 1/20 0.33
DYRK2 Q92630 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1323657 0.76 TDP1 (0.45) CYP1A2LMNAKMT2AMEN1ALDH1A1
SCHEMBL9692146 0.76
SCHEMBL2893718 0.73 HSD17B10 (0.41) HSD17B10CYP1A2LMNATHRBBLM
SCHEMBL14641228 0.73 DYRK1A (0.36) HSD17B10CYP1A2LMNATHRBBLM
SCHEMBL9104761 0.73 MAPT (0.40) LMNADYRK1AKMT2AMEN1MAPT
SCHEMBL28520422 0.73
SCHEMBL32909 0.73
SCHEMBL10351402 0.71 HSD17B10 (0.39) HSD17B10CYP1A2LMNATHRBBLM
SCHEMBL8213611 0.71 HSD17B10 (0.39) HSD17B10CYP1A2LMNATHRBBLM
SCHEMBL2491794 0.71 ALDH1A1 (0.47) HSD17B10CYP1A2LMNATHRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114108367-B Method for preparing modified cationic starch by dry method 上海东升新材料有限公司 2023-03-17 CN claimed
CN-114958320-A Silicate-cholate-hydroxypropyl guar gel for profile control and preparation method thereof 滨州学院 2022-08-30 CN claimed
CN-114108367-A Method for preparing modified cationic starch by dry method 上海东升新材料有限公司 2022-03-01 CN claimed
US-20240425478-A1 CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS GENENTECH INC (US) 2024-12-26 US disclosed
CN-113583144-B Preparation method and application of one-way memory flocculant 石河子大学 2023-07-18 CN disclosed
CN-114108367-B Method for preparing modified cationic starch by dry method 上海东升新材料有限公司 2023-03-17 CN disclosed
CN-114958320-A Silicate-cholate-hydroxypropyl guar gel for profile control and preparation method thereof 滨州学院 2022-08-30 CN disclosed
CN-114108367-A Method for preparing modified cationic starch by dry method 上海东升新材料有限公司 2022-03-01 CN disclosed
CN-113583144-A Preparation method and application of one-way memory type flocculating agent 石河子大学 2021-11-02 CN disclosed
EP-3355699-B1 BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 ONCOTHERAPY SCIENCE INC (JP) 2021-03-31 EP disclosed
US-20180273529-A1 BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 ONCOTHERAPY SCIENCE, INC. (JP) 2018-09-27 US disclosed
CN-101448397-A Selective benzylamine derivatives and their use as cholesteryl ester transfer protein inhibitors REDDY US THERAPEUTICS INC (US) 2009-06-03 CN disclosed
EP-1981342-A1 SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS Reddy US Therapeutics, Inc. (US) 2008-10-22 EP disclosed
WO-2007075194-A1 SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS REDDY US THERAPEUTICS, INC. (US) 2007-07-05 WO disclosed
WO-2007075194-A1 SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS REDDY US THERAPEUTICS, INC. (US) 2007-07-05 WO disclosed
US-20070015758-A1 Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2007-01-18 US disclosed
US-20070015758-A1 Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2007-01-18 US disclosed
US-20070015758-A1 Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2007-01-18 US disclosed
US-4753940-A PARASITICIDE, ANTHELMINTIC CIBA-GEIGY CORPORATION (US) 1988-06-28 US disclosed
US-4016013-A OR CARBONITRIDESDECOMPOSITION OF TRIAZINE OR PYRIMIDINE COMPOUNDS CIBA-GEIGY CORPORATION (US) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425478-A1 CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS CDK2, CCNI, CDK20 HSD17B10 3403/4885CYP1A2 960/4885LMNA 1610/4885
US-20180273529-A1 BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 SUV39H2, SUV39H1, EZH1 HSD17B10 664/4885CYP1A2 3455/4885LMNA 3773/4885
US-20070015758-A1 Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors CETP, NPC1, DBI HSD17B10 354/4885CYP1A2 2839/4885LMNA 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.